ClinicalTrials.gov
public full text
Public Domain
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
This study will evaluate whether visual interpretation of flortaucipir-PET (positron emission tomography) scans, examining patterns of tracer uptake at baseline, can predict the rate of clinically-meaningful cognitive decline due to AD after 18 months. All scans are acquired from cohorts of a previously completed study, I8D-MC-AZES (NCT02245737, lanabecestat, Eli Lilly and Company sponsor).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- No evidence of cognitive or psychological impact after returning research Alzheimer disease biomarkers: A delayed-start, noninferiority, randomized clinical trial#321482
- Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease#908696
- F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)#1140812
- SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid#886116
- Divergent trends in Alzheimer's disease burden: a comparative analysis of the US and G20 nations.#472667
Record · ID 891236
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive